

## Pharmakogenetik in der Praxis: warum, wie, wann? Teil 2

## Pharmacogénétique dans la pratique: pourquoi, comment, quand? Partie 2

### Literatur

1. van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. *Eur Heart J*. 2011;32(15):1909–17.
2. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. *N Engl J Med*. 2009;360:753–64.
3. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy. *Clin Pharmacol Ther* 2011;90(2):328–32.
4. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy—a genome-wide study. *N Engl J Med*. 2008;359:789–99.
5. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? *Antimicrob Agents Chemother*. 2005;49:1733–8.
6. Hiratsuka M, Kishikawa Y, Takekuma Y, Matsuura M, Narahara K, Inoue T, et al. Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. *Drug Metab Pharmacokinet*. 2002;17:357–62.
7. Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. *Br J Rheumatol*. 1997;36:1089–94.
8. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. *Am J Hum Genet*. 1980;32:651–62.
9. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. *Clin Pharmacol Ther*. 2011;89:387–91.
10. Wusk B, Kullak-Ublick GA, Rammert C, von Eckardstein A, Fried M, Rentsch KM. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. *Eur J Gastroenterol Hepatol*. 2004;16:1407–13.
11. Michaud V, Bar-Magen T, Turgeon J, Flockhart D, Desta Z, Wainberg MA. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. *Pharmacol Rev*. 2012;64:803–33.
12. Stieger B, Meier PJ. Pharmacogenetics of drug transporters in the enterohepatic circulation. *Pharmacogenomics*. 2011;12:611–31.
13. Ross JR, Riley J, Taegtmeyer AB, Sato H, Gretton S, du Bois RM, et al. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. *Cancer*. 2008;112:1390–403.
14. Chowbay B, Kumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. *Pharmacogenetics*. 2003;13:89–95.
15. Taegtmeyer AB, Breen JB, Smith J, Burke M, Leaver N, Pantelidis P, et al. ATP-binding cassette subfamily B member 1 polymorphisms do not determine cyclosporin exposure, acute rejection or nephrotoxicity after heart transplantation. *Transplantation*. 2010;89:75–82.
16. Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. *Handb Exp Pharmacol*. 2011:261–83.
17. Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A, et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. *Clin Pharmacol Ther*. 2008;84:75–82.
18. Genetic Testing for Hereditary Familial Cholestatic Liver Diseases. (<http://www.pharmacogenetics.ch>), 2012. Accessed 25.05.2012.
19. Waters MD, Fostel JM. Toxicogenomics and systems toxicology: aims and prospects. *Nat Rev Genet*. 2004;5:936–48.

20. Youns M, Hoheisel JD, Efferth T. Toxicogenomics for the prediction of toxicity related to herbs from traditional Chinese medicine. *Planta Med.* 2010;76:2019–25.
21. Khor TO, Ibrahim S, Kong AN. Toxicogenomics in drug discovery and drug development: potential applications and future challenges. *Pharm Res.* 2006;23:1659–64.
22. Van Hummelen P, Sasaki J. State-of-the-art genomics approaches in toxicology. *Mutat Res.* 2010;705:165–71.
23. Kienhuis AS, Bessems JG, Pennings JL, Driessen M, Luijten M, van Delft JH, et al. Application of toxicogenomics in hepatic systems toxicology for risk assessment: acetaminophen as a case study. *Toxicol Appl Pharmacol.* 2011;250:96–107.
24. Ferrer-Dufol A, Menao-Guillen S. Toxicogenomics and clinical toxicology: an example of the connection between basic and applied sciences. *Toxicol Lett.* 2009;186:2–8.
25. Cui Y, Paules RS. Use of transcriptomics in understanding mechanisms of drug-induced toxicity. *Pharmacogenomics.* 2010;11:573–85.
26. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, et al. Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. *Gastroenterology.* 2011;141:338–47.